Shots:

• The FDA has approved the Ventana MMR RxDx Panel test as a CDx to identify patients with dMMR advanced solid tumors- who may be eligible for Jemperli monothx.- based on the results of the MMR biomarker test
• Ventana MMR RxDx Panel provides access to clinicians with fully automated panel of MMR biomarkers tested by IHC
• The test assesses the expression of MMR proteins in FFPE tumor tissues. The test and Jemperli were earlier received approval for use in endometrial cancer in Apr’2021

Ref: Roche | Image: Roche